STRM.BIO, a pre-clinical biotechnology company pioneering gene therapies utilizing extracellular vesicles (EVs) to treat rare blood diseases, today announced the appointment of Dawn Bell, PharmD to its Board of Directors.
With a wealth of experience in the life science industry, spanning from academic spinouts to large pharmaceutical companies, Dr. Bell most recently held leadership positions at Novartis in areas such as global drug development, medical affairs, and portfolio strategy.
We are thrilled to have Dawn join our Board of Directors, as her strong strategic and operational expertise and leadership will be an incredible asset to STRM.BIO. With an impressive history of creating value and growing companies in the biopharmaceutical industry, Dawn’s experience and knowledge will be invaluable as we continue to develop cutting-edge gene therapies.
Dr. Bell is an experienced executive in the pharmaceutical industry. At Novartis, she achieved an incredible feat by securing FDA Break-Through and Fast-Track status, and delivering the approval of Entresto ($4B) 18 months ahead of schedule.
As VP of Clinical Development and Medical Affairs and a member of the Executive Team for Novartis Canada, she was responsible for the launch of eight medicines across five therapeutic areas in four years, including the first two gene therapies approved in Canada (Zolgensma® and Luxturna®).
Before Novartis, she was the founding CEO of an Emory University spinout, GM of a commercial-stage rare disease company, and early commercial leader at The Medicines Company, where she contributed to the company’s market cap growth from $400M to $2B within three years. Dr. Bell earned her PharmD from the University of Florida.
Dr. Bell is excited to join the STRM.BIO Board and work closely with the leadership team and other Board members. He is deeply impressed by the team at STRM.BIO and the potential of their platform to revolutionize the delivery of gene therapies, providing the opportunity to treat a variety of diseases and conditions with unmet needs. This is an incredibly important time for the company and he looks forward to being a part of it.
STRM.BIO is revolutionizing the world of medicine by leveraging extracellular vesicles (EVs) to deliver gene therapies in a simpler, safer, and more practical way. Based in Boston, MA, this pre-clinical, VC-backed biotechnology company is unlocking the potential of gene therapy to bring hope to patients living with rare diseases around the world. STRM.BIO is determined to make gene therapy a reality.